GoodRx agrees to $32M settlement. Who's eligible for money?

GoodRx agreed to a $32M settlement to resolve a class-action lawsuit alleging it shared users' health information with third parties. The settlement, pending court approval, covers users who used GoodRx services before April 20, 2024. Claims can be submitted until Dec. 29, with payments depending on the number of approved claims and court processes.

Original reporting
Published Nov 18, 2026, 3:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 3:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GoodRx agrees to $32M settlement. Who's eligible for money? — source image
Decision brief

The 30-second read

$GDRXNeutralLow
01

Why it matters

The key tradable element is the $32M settlement and the procedural milestones (claims now, court approval Feb. 11, 2027), which can influence legal-risk pricing and any expectation of additional claims.

02

Market read

Settlement details and eligibility and claim deadlines can affect investor perception of legal exposure, though the article provides no earnings or guidance impact.

03

What to watch

Traders may be underweighting the timeline risk: payments depend on court approval and claim participation rates, which can affect perceived finality and any future litigation appetite.

Relevance 6/10Novelty 6/10Timing: claims open now; final approval hearing set for Feb. 11, 2027

Background

The article describes a class-action settlement tied to allegations that GoodRx shared users’ health information with analytics and advertising companies, including Criteo.

Company-level read

Ticker impact

$GDRXNeutralMedium confidence
Context

GoodRx agreed to a $32M class-action settlement over alleged sharing of users’ health data with analytics and advertising partners, including Criteo.

Expected impact

Likely limited immediate upside, with any move driven by how investors price legal risk and settlement finality rather than fundamentals.

Evidence & confidence

The article is a settlement announcement with a defined fund size and claim process, but it does not provide guidance changes or a clear magnitude relative to earnings, so price impact is likely modest.

Market effects

Highlights ongoing regulatory and litigation risk around health-data privacy for digital health and prescription-discount platforms.

Primarily US-focused consumer class-action process; limited direct cross-market spillover.

Moderate, as privacy litigation frameworks and ad-tech data-sharing scrutiny are globally relevant.

Counterpoint

Because the settlement excludes Meta and Google and does not indicate an admission of wrongdoing, the market may treat it as a contained cost rather than a signal of broader systemic liability.

Key entities

  • GoodRx

    Digital health care company that agreed to a $32 million class-action settlement over alleged health-data sharing.

  • Criteo

    Advertising/analytics company named in the lawsuit; both parties denied allegations but settled with plaintiffs.

  • Meta

    Named as a defendant in the lawsuit, but excluded from the settlement described in the article.

  • Google

    Named as a defendant in the lawsuit, but excluded from the settlement described in the article.

Related articles

$GDRXMed

GoodRx stock rises on Google Cloud healthcare AI partnership

GoodRx Holdings (GDRX) stock rose 4.7% premarket after announcing a partnership with Google Cloud's Gemini for healthcare. The integration allows healthcare enterprises to access GoodRx pricing data within AI workflows, expanding distribution for GoodRx's prescription savings programs. The company plans to extend this integration to other AI platforms.

$OSCRMed

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

$GDRXHigh

GOODRX REPORTS SECOND QUARTER 2026 RESULTS

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2026 RESULTS Pharma Direct and Subscription Revenue Increased 76% and 39% , Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adjusted EBITDA Expectations SANTA MONICA, Calif. -- ( August 5, 2026 ) -- GoodRx Holdings